iktos.ai

What It Is

Iktos is an AI drug discovery company based in Paris, France, focused on small-molecule R&D. Its platform connects generative AI, AI retrosynthesis, and robotic automated labs, aiming to accelerate the workflow from molecular design to preclinical candidates. The company claims it can shorten the discovery phase to under 2 years.

Core Capabilities

Its core products include Makya, Spaya, and Iktos Robotics. Makya is a generative AI SaaS platform designed for medicinal chemists, used for de novo molecule design. It emphasizes diversity, novelty, medchem-like properties, synthetic accessibility, multi-parameter optimization, and 3D constraints. Spaya handles AI-driven retrosynthesis, displaying routes in real time and supporting custom synthetic steps and constraints, linking target compounds to commercially available starting materials. The robotics platform further covers synthesis, purification, analysis, testing, and high-throughput data iteration, forming a closed-loop DMTA workflow. The official website also mentions Iktos Engine APIs, but does not provide details on specific API capabilities.

Pricing and Trial

The available materials do not disclose pricing, plans, free quotas, or trial options. Iktos appears to lean more toward enterprise partnerships and project-based R&D services. Prospective customers will need to contact the sales or partnership team to confirm purchasing models, deployment options, data rights, and service boundaries.

Pros and Cons

Its strength lies in the relative completeness of the platform chain, covering design, retrosynthesis, automated experimentation, and biological data feedback. The use cases are clearly defined, making it suitable for medicinal chemistry and computational chemistry teams. The website states that Iktos has over 60 collaborations with pharmaceutical, biotech, and academic organizations, as well as an internal pipeline and support from the EIC Accelerator. The limitations are a lack of transparency around key information, including model architecture, training data, performance benchmarks, data privacy, security compliance, Chinese-language support, and pricing. The quality of its outputs also needs to be judged through target-specific projects and experimental validation, rather than inferred solely from website claims.

Who It’s For and Access from China

Iktos is better suited to pharmaceutical companies, biotech firms, CROs/research institutions, and teams with small-molecule R&D pipelines. It is not aimed at general AI tool users. The official website does not specify access conditions from China, and network connectivity, payment methods, and local support are all unknown. For alternatives, users may compare it with AI drug discovery or computational chemistry platforms such as Schrödinger, Exscientia, Insilico Medicine, Atomwise, and Recursion.